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Abstract 
Introduction: Over 50% of patients with colorectal cancer (CRC) will progress and/or de-
velop  metastases.  Biomarkers  capable  of  predicting  progression,  risk  stratification  and 
therapeutic benefit are needed. Cancer stem cells are thought to be responsible for tumor 
initiation, dissemination and treatment failure. Therefore, we hypothesized that CRC cancer 
stem cell markers (CRCSC) will identify a group of patients at high risk for progression.  
Methods:  Paraffin-embedded  tissue  cores  of  normal  (n=8),  and  histopathologically 
well-defined primary (n= 30) and metastatic (n=10) CRC were arrayed in duplicate on tissue 
microarrays (TMAs). Expression profiles of non-CD133 CRCSC (CD29, CD44, ALDH1A1, 
ALDH1B1, EpCam, and CD166) were detected by immunohistochemistry and the association 
with clinicopathological data and patient outcomes was determined using standard statistical 
methodology. An independent pathologist, blinded to the clinical data scored the samples. 
Scoring included percent positive cells (0 to 4, 0 = <10%, 1 = 10 – 24%, 2 = 25 – 49%, 3 = 50 
– 74%, 4 = 75 – 100%), and the intensity of positively stained cells (0 to 4; 0 = no staining, 1 = 
diminutive intensity, 2 = low intensity, 3 = intermediate intensity, 4 = high intensity). The 
pathologic score represents the sum of these two values, reported in this paper as a combined 
IHC staining score (CSS).  
Results: Of 30 patients 7 were AJCC stage IIA, 10 stage IIIB, 7 stage IIIC and 6 stage IV. Median 
follow-up was 113 months. DFI was 17 months. Median overall survival (OS) was not reached. 
Stage-specific OS was: II – not reached; III – not reached; IV – 11 months. In a univariate 
analysis, poor OS was associated with loss of CD29 expression; median OS, 32 months vs. not 
reached for CSS 3-7 vs. >7.5, respectively; p=0.052 comparing entire curves, after adjustment. 
In a Cox model analysis, loss of CD29 exhibited a trend toward association with survival 
(p=0.098) after adjusting for the effect of stage (p=0.0076). Greater expression of ALDH1A1 
was associated with increasing stage (p=0.042 over stages 2, 3b, 3c, and 4) while loss of CD29 
expression exhibited a trend toward being associated with stages 3 and 4 (p=0.08). Compared 
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to  normal  colon  tissue,  primary  tumors  were  associated  with  increased  expression  of 
ALDH1B1 (p=0.008). ALD1H1B1 expression level differed according to whether the tumor 
was moderately or poorly differentiated, well differentiated, or mucinous; the highest ex-
pression levels were associated with moderately or poorly differentiated tumors (p=0.011). 
Lymph node metastases were associated with a trend toward decreased expression of Ep-
CAM (p = 0.06) when comparing 0 vs. 1 vs. 2+ positive lymph nodes, as was CD29 (p = 0.08) 
when comparing 0 vs. any positive lymph nodes. Compared to normal colon tissue metastatic 
colon cancers from different patients were associated with increased ALDH1B1 expression 
(p=0.001) whereas CD29 expression was higher in normal colonic tissue (p=0.014). 
Conclusion: CD29 may be associated with survival as well as clinical stage and number of 
lymph nodes. ALDH1B1 expression was associated with differentiation as well as type of 
tissue evaluated. ALDH1A1 was associated with clinical stage, and decreased EpCAM ex-
pression was found in patients with advanced lymph node stage. CRCSCs may be useful 
biomarkers to risk stratify, and estimate outcomes in CRC. Larger prospective studies are 
required to validate the current findings. 
Key words: colon cancer, staging, lymph node, cancer recurrence, overall survival, prognosis, bi-
omarkers, cancer stem cells. 
Introduction 
Colorectal cancer (CRC) is the third most com-
mon cause of cancer-related death in the US 1. One out 
of four patients presenting with conventionally staged 
node negative disease (AJCC Stage I and II), and over 
50%  of  patients  with  Stage  III  disease  will  develop 
local  recurrence  and/  or  metastases2,3.  Across  all 
stages,  approximately  30%  of  patients  will  develop 
distant  metastases2.  Once  metastases  become  clini-
cally  evident  prognosis  is  often  fatal.  Moreover,  in 
spite of the fact that modern systemic therapies for 
CRC have resulted in improved overall survival (OS), 
failure rate in the adjuvant setting is 30% for high-risk 
Stage II and Stage III patients, and overall response 
rate is only 60% for patients with Stage IV CRC 4,5,6. A 
significant advance in the care of patients will be re-
alized by biomarkers that can accurately identify pa-
tients  at-risk  for  disease  recurrence  and  dissemina-
tion, and those that fail to respond to systemic thera-
py. These patients might benefit from early (preven-
tative)  treatment,  alternative  treatment  strategies, 
and/or frequent surveillance for and early detection 
of disease recurrence.  
Extensive CRC research over the last decade has 
suggested  promising  biomarkers7.  Although  many 
biomarkers  exist,  only  a  select  few  have  provided 
prognostic  data.  This  list  includes  markers  such  as 
tumor MSI-H expression (defects in DNA mismatch 
repair,  MSI  phenotype),  18q  AI  expression,  p53  ex-
pression and KRAS mutation. MSI-H phenotype has 
been  associated  with  improved  clinical  outcome 
(disease-free and overall survival) 8,9. Some published 
data supports the recommendation not to administer 
chemotherapy to Stage II patients with a MSI-H pri-
mary colon cancer 10. The overall predictive value of 
MSI-H  phenotype  is  currently  being  tested  in  the 
Eastern  Cooperative  Oncology  Group  Trial  5202 
(E5202) adjuvant CRC trial  7. This trial is specifically 
intended to identify patients with AJCC Stage II CRC 
most likely to respond to adjuvant systemic therapy. 
Tumor expression of 18q AI has also been asso-
ciated with decreased survival and is also being tested 
in  the  E5202  trial7.  Furthermore,  p53  mutation  or 
overexpression has been associated with poor prog-
nosis, including decreased disease free survival (DFS), 
recurrence  free  survival  (RFS)  and  overall  survival 
(OS)7. Although KRAS itself is not a prognostic factor 
in CRC, patients with wild-type KRAS tumors have 
been  found  to  respond  to  and  benefit  from  certain 
targeted adjuvant systemic therapies7,11,12. That being 
said, the overall poor survival of advanced CRC pa-
tients  establishes  the  need  for  improved  prognostic 
and predictive biomarkers.  
The  precise  cell  of  origin  of  CRC  remains  un-
known. Recently, compelling evidence has emerged 
in support of the cancer stem cell (CSC) hypothesis in 
several solid organ epithelial malignancies including 
CRC13,14,15-18. The CSC hypothesis posits that CSCs are 
responsible  for  tumor  initiation,  metastases  and  re-
sistance  to  treatment  leading  to  disease  relapse  fol-
lowing  surgery  and/or  chemoradiotherapy19.  The 
traditional,  stochastic  model  of  tumorigenesis  sug-
gests that all cells within a tumor are capable of tumor 
initiation  and  propagation20.  The  CSC  hypothesis 
proposes a hierarchical model, in which only a small 
fraction of cells (CSC) are capable of tumor propaga-
tion20. The CSC hypothesis therefore raises questions 
regarding current diagnostic and therapeutic modali-
ties, suggesting that the CSC is a rational target for the  Journal of Cancer 2012, 3 
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development of more efficacious screening, early de-
tection,  prevention,  treatment  and  surveillance  mo-
dalities and interventions20,21. Based on the tenets of 
the CSC hypothesis, identification, proper selection, 
characterization,  testing,  biological  implications  and 
validation of CRC derived CSC (CRCSC) are impera-
tive  for  improving  early  detection,  screening,  risk 
stratification prognostication and individualized pre-
diction of treatment response. 
Properties  that  define  potential  CSCs  are:  [1] 
self-renewal;  [2]  the  capacity  for  differentiation  (al-
lowing for recapitulation of all cell types of the origi-
nal  tumor);  [3]  tumor  initiating  capacity;  and,  [4] 
asymmetric cell division via non-random chromoso-
mal co-segregation16,22. Investigators have used these 
properties  and  various  membrane  and  cytoplasmic 
markers  to  isolate  putative  CRCSC:  CD133,  CD29, 
CD44,  CD166  (ALCAM),  EpCAM,  ALDH1A1  and 
ALDH1B1 (Table 1). These markers represent all re-
ported CRCSC. Despite the potential of CRCSC’s to be 
utilized  as  clinically  relevant  biomarkers,  little  is 
known  about  the  prognostic  value  of  non-CD133 
CRCSC  markers23.  Notwithstanding,  the  CSC  hy-
pothesis may herald a paradigm shift in screening and 
early detection in CRC once the precise role of CRCSC 
markers  is  further  established.  Therefore,  we  hy-
pothesized  that  CRCSC  markers  can  be  used  as  bi-
omarkers to predict disease progression, and identify 
patients at risk for recurrence.  
Until more effective therapies can be developed, 
one strategy for improving outcomes while reducing 
the socio-economic burden of CRC is to develop novel 
strategies for CRC screening that will result in higher 
rates of early CRC detection. Another strategy to im-
prove outcomes in this era of patient-centered, quali-
ty-driven, value-based purchasing in  oncology is  to 
identify those patients who would most benefit from 
adjuvant  treatments  and  intensive  post-treatment 
surveillance  protocols.  There  is  an  acute  need  for 
highly  sensitive  and  specific  biomarkers  capable  of 
identifying  patients  with  early  CRC  that  are  highly 
likely to recur and/ or metastasize, and patients who 
are likely to progress despite adjuvant therapy. Such 
risk stratification would: [1] spare low risk patients 
likely cured by surgery alone the toxicity of systemic 
therapy;  [2]  identify  and  treat  with  chemotherapy 
at-risk patients with early stage CRC; and, [3] limit 
treatments  to  patients  with  clinically  latent  (stable) 
residual  disease  and  reserve  additional  therapy  for 
treatment-responsive disease progression 24. The aim 
of this pilot study was to analyze the expression pro-
file of non-CD133 putative CRCSC markers and de-
termine a possible role for CRCSC as risk-stratifying, 
prognostic biomarkers.  
Table 1. Summary of putative CRC Stem Cell Markers. 
Marker  Gene  Function 
CD29  ITGB1  - Integrin that mediates cell-ECM adhesion 
and is involved in homing to sites of in-
flammation 
-Involved in cell growth, differentiation, 
migration and death 
CD44  CD44  -Cell surface glycoprotein involved in cell 
adhesion and migration 
-Associated with malignant progression 
(adenoma to carcinoma): involved in cell 
migration through the ECM  
-Enhanced expression in breast cancer epi-
thelial cells facilitated tumor cell migration  
 
CD166  ALCAM  -Involved in neuronal extension, embryonic 
hemopoiesis, embryonic angiogenesis 
-Cell adhesion molecule 
-Associated with adenoma to carcinoma 
development 
 
EpCAM  EPCAM  -Cell adhesion molecule 
-Linked to Cadherin-Cathenin pathway and 
Wnt pathway 
-Expression data linked to poorer survival 
times in several tumor types including 
breast cancer 
-Loss of expression associated with aggres-
sive rectal cancer 
 
ALDH1A1 ALDH1A1 -Detoxifying enzyme responsible for the 
oxidation of intracellular aldehydes  
-Early differentiation of stem cells  
-Involved in resistance to chemotherapy 
(alkylating agents) 
-Malignant prostate stem cells and predictor 
of prostate cancer patient outcome 
 
ALDH1B1  ALDH1B1  -Detoxifying enzyme responsible for the 
oxidation of intracellular aldehydes  
-Early differentiation of stem cells  
-Higher expression in CRC 
 
Abbreviations: CD, cluster of differentiation; ALDH, aldehyde 
dehydrogenase-1; ECM, extra cellular matrix; CRC, colorectal can-
cer. 
 
Methods 
Patients  
We used a colorectal Tissue Micro Array (TMA) 
with corresponding survival and clinicopathological 
data  (catalog  number  C0951,  US  Biomax,  Rockville, 
MD, USA). The TMA included 30 patients with dou-
ble core tissue sites of primary colorectal cancers with 
matched normal colorectal tissue in eight patients and 
matched  metastatic  tissue  in  ten  other  patients.  Pa-
tient characteristics are depicted in table 2.  
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Table 2. Summary of patient characteristics (n = 30). 
Clinicopathological 
Feature 
Outcome  Frequency N 
(%) 
Age (years; n = 29) 
 
Mean (range) 
 
56 (35 – 76) 
Gender (n = 30) 
 
 
Male  17 (57) 
 
Female 
 
13 (43) 
Location (n = 30) 
 
 
 
 
 
 
Sigmoid colon  11 (36.6) 
Ascending colon  8 (26.6) 
Transverse colon  3 (10) 
Descending colon  2 (6.6) 
Cecum  2 (6.6) 
Rectum 
 
4 (13.3) 
Pathological Grade (n = 
30) 
 
 
 
 
Poorly differentiated  1 (3.3) 
Moderately differentiated  18 (60) 
Well differentiated  8 (26.6) 
Mucinous Adenocarcinoma  3 (10) 
Stage (n = 30) 
 
 
 
 
 
IIA 
 
7 (23.3) 
IIIB  10 (33.3) 
IIIC  7 (23.3) 
IV  6 (20) 
T Classification (n = 30) 
 
 
 
pT3 
 
25 (83.3) 
pT4  5 (16.6) 
N Classification (n = 30) 
 
 
 
 
N0 
 
7 (23.3) 
N1  13 (43.3) 
N2  10 (33.3) 
Sites of Metastatic Tis-
sue 
(n = 8) 
 
 
 
Lung 
 
2 
Lymph node  5 
Ovary  3 
Follow Up (months) 
 
Median (Range) 
 
113 (0 – 130) 
 
 
 
Immunohistochemistry 
Immunohistochemistry  (IHC)  was  performed 
using  previously  described  techniques25.  We  per-
formed  immunohistochemistry  for  CD29,  CD44, 
CD166, EpCam, ALDH1A1 and ALDH1B1 (Table 1). 
Staining  was  performed  on  Leica  Biosystems  (IL, 
USA) Bond Autostainer. The primary antibodies used 
in  this  study  included  anti-CD29  (1:200,  Abcam, 
Cambridge,  MA,  USA),  anti-CD44  (1:400,  Abcam, 
Cambridge,  MA,  USA),  anti-CD166  (1:40,  Abcam, 
Cambridge, MA, USA), anti-EpCam (1:100, Cell Sig-
naling,  Danvers,  MA,  USA),  anti-ALDH1A1  (1:250, 
Epitomics,  Burlingame,  CA,  USA),  anti-ALDH1B1 
(1:400, Sigma, St. Louis, MO, USA). TMAs were single 
stained for each biomarker with matched positive and 
negative controls25. A pathologist who was blinded to 
the  clinical  outcomes  evaluated  individual  samples 
within the TMAs. Each individual sample was scored 
quantitatively  evaluating  the  proportion  of  positive 
cells, and the intensity of positively stained cells. The 
percent  of  positive  cells  was  graded  using  the  fol-
lowing rubric: 0 = <10%, 1 = 10 – 24%, 2 = 25 – 49%, 3 
= 50 – 74%, 4 = 75 – 100%. The intensity of positive 
stained cells was graded using the following rubric: 0 
= no staining, 1 = diminutive intensity, 2 = low inten-
sity, 3 = intermediate intensity, 4 = high intensity. The 
pathologic score for each sample is represented by the 
sum of these two values: this sum is referred to as the 
combined IHC staining score (CSS).  
Statistical Analyses 
CSS  was  computed  for  each  sample  and  each 
marker.  In  cases  in  which  there  were  two  samples 
obtained for a given patient/site, the average of the 
sum of the two scores was used. The association be-
tween the pathologic score and overall survival (OS) 
of patients was determined based on data from the 30 
primary sites. The probability of survival as a function 
of time was determined by the Kaplan-Meier method, 
and the statistical significance was determined by the 
log-rank  method.  In  cases  for  which  the  initial 
grouping of patients’ scores or clinical data was re-
duced  to  two  groups  in  order  to  identify  a  better 
grouping of subjects based on prognostic ability, the 
p-values  for  the  revised  analysis  of  dichotomized 
groups  were  adjusted  for  multiple  testing,  which 
would be performed to arrive at the identified final 
grouping. A Cox proportional hazards model analysis 
was performed to determine the joint association of 
CSSs found to be significantly associated with OS in 
the initial univariate analyses after adjusting for im-
portant clinical factors. 
Within the 30 primary specimens, the association 
between the CSS and tumor grade was determined 
with  an  exact  Kruskal-Wallis  test.  The  association 
between  the  CSS  and  stage  was  determined  by  a 
Jonckheere-Terpstra  test  for  trend.  The  association 
between the CSS and sex was determined by an exact 
Wilcoxon rank sum test, while Spearman rank corre-
lation was used to determine the correlation between 
the CSS and age. Analyses to compare the CSS be-
tween the matched primary sites and the metastatic 
sites, or the primary sites and the normal sites, were 
performed  on  paired  samples  using  a  Wilcoxon  Journal of Cancer 2012, 3 
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signed rank test. Comparisons of CSS between meta-
static  and  normal  samples  were  made  with  a  Wil-
coxon rank sum test, since these data are only from 
different  patients.  All  p-values  are  two-tailed  and 
presented without adjustment for multiple compari-
sons. 
Results 
All six CRCSC markers were assessed for asso-
ciation with overall survival. Out of the six, only loss 
of CD29 expression was potentially associated with a 
significant  difference  in  OS  (CSS  3-7  vs.  CSS  >  7.5, 
median 32 months vs. not reached, respectively; p = 
0.052  after  adjustment  for  the  grouping  identified, 
Figure 1, 2). Increased ALDH1A1showed a trend to-
wards decreased OS (p=0.16, Table 3). Age, sex, and 
pathologic grade (poorly, moderately, well differen-
tiated)  were  not  significantly  associated  with  OS. 
Stage of disease was associated with OS; patients with 
AJCC Stage 2 or 3 disease had a significantly better 
prognosis  than  those  with  Stage  4  disease  (Median 
OS: not reached vs. 11 months; p = 0.0009, adjusted for 
the grouping of stages). The joint association between 
CD29 and Stage (2-3 vs. 4) was evaluated in a Cox 
proportional hazards model. After adjusting for stage 
(p=0.0076, Hazard ratio 5.06; 95% CI for HR: 1.54 to 
16.65), loss of CD29 expression was marginally asso-
ciated  with  poor  OS  (p  =  0.098;  Hazard  ratio=0.28; 
95% CI for HR: 0.06 to 1.27; Figure 2).  
Univariate analyses of the CSS were performed 
for the 30 primary tissue specimens in order to assess 
the interaction between the CRCSC biomarkers and 
the level of pathologic differentiation (poorly, mod-
erately,  well  differentiated).  Out  of  the  six  CRCSC, 
only ALDH1B1 showed a statistically significant as-
sociation  with  tumor  differentiation.  ALDH1B1  ex-
pression was significantly increased in poorly and/or 
moderately  differentiated  tumors  as  compared  to 
well-differentiated  or  mucinous  tumors  (p  =  0.011). 
Analysis  of  the  association  between  CSS  and  stage 
was performed. Only increased ALDH1A1 showed an 
association between increasing expression level and 
increasing stage (p = 0.04). The combination of CD29 
and ALDH1B1 was not associated with a difference in 
OS. 
When comparing normal colon tissue to meta-
static  tissue  sites  from  different  patients,  CD29  ex-
pression  was  higher  in  normal  tissue  (p  =  0.014), 
whereas  ALDH1B1  expression  was  significantly 
higher in metastatic tissue (p = 0.001). In comparing 
primary  tumors  to  their  matched  patient  metastatic 
sites, none of the CSS differed significantly between 
two samples from the same patient. However, com-
parison  of  normal  colon  tissue  to  primary  tumor 
showed that increased ALDH1B1 expression was as-
sociated with the primary tumors (p = 0.008). 
Table 3. Association of CRCSC with survival and clinical 
characteristics. (Overall Survival Statistics) 
Marker  Expression  p-value 
Overall Survival Statistics 
CD29  Decreased  0.052 (adjusted for 
grouping) 
CD44  -  0.69 
CD166  -  0.33 
EpCAM  -  0.77 
ALDH1A1  -  0.16 
ALDH1B1  -  0.27 
Pathologic Differentiation (poorly/moderately differentiated vs. 
well differentiated vs. mucinous) 
CD29  -  0.55 
CD44  -  0.94 
CD166  -  0.75 
EpCAM  -  0.09 
ALDH1A1  -  0.30 
ALDH1B1  Increased  0.011 
Increasing Stage of Disease 
CD29  -  0.19 
CD44  -  0.38 
CD166  -  0.77 
EpCAM  -  0.34 
ALDH1A1  Increased  0.04 
ALDH1B1  -  0.97 
Normal vs. Metastatic Tissue 
CD29  Decreased  0.014 
CD44  -  0.26 
CD166  -  0.23 
EpCAM  -  0.10 
ALDH1A1  -  0.24 
ALDH1B1  Increased  0.001 
Normal vs. Primary Tumor Tissue 
CD29  -  0.44 
CD44  -  0.84 
CD166  -  0.13 
EpCAM  -  0.50 
ALDH1A1  Increased   0.06 
ALDH1B1  Increased   0.008 
Lymph Node Stage 
CD29  Decreased   0.08 (0 vs. 1+2; p=0.11 
for 0 vs. 1 vs. 2) 
CD44  -  0.57 
CD166  -  0.52 
EpCAM  Decreased   0.06 
ALDH1A1  -  0.47 
ALDH1B1  -  0.65 
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Figure 1. A. Immunohistochemistry anti-CD29 staining, CSS 5 at 8x and 20x ocular. B. Immunohistochemistry anti-29 staining, CSS 8 at 
8x and 20x ocular. (CSS: combined staining score). 
 
 
 
Figure 2. Association of overall survival and CD29 expression of the primary colorectal cancer tumor. Combined staining score was 
calculated as the sum of antibody intensity (0 – 4) and percent cells positive (0 – 4). 
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Assessment of the six CRCSC markers and their 
relation  to  lymph  node  status  was  performed.  Ad-
vanced  AJCC  lymph  node  stage  (N0  vs.  N1-2)  was 
associated with decreased CD29 (p = 0.08) expression, 
while  EpCAM  tended  to  decrease  with  increased 
nodal stage, from N0 to N1 to N2; p=0.06.  
Localization of expression was different between 
the various CRCSC markers, and consistent with pre-
vious  reports  and  their  associated  functions. 
ALDH1A1 and ALDH1B1 expression was intracellu-
lar, while EpCAM expression was at the cell surface. 
CD29, CD44 and CD166 had a combination of intra-
cellular and cell surface expression.  
Discussion 
Two  fundamental  issues  regarding  colorectal 
carcinogenesis remain unanswered. First, the level of 
differentiation in the initiating neoplastic cell has not 
been well described i.e. colonic stem cell vs. differen-
tiated mature colonic mucosal epithelial cell. Second, 
since  tumors  are  well  known  to  be  composed  of  a 
heterogeneous group of cells, the specific identity of 
tumor cells that lead to lymph-node involvement, and 
metastatic disease is not well characterized.20 Recent-
ly, attempts to address both of these issues pragmati-
cally, which are critical to our understanding of tumor 
biology,  have  resulted  in  the  description  of  cancer 
stem cells. While the stochastic model of tumorigene-
sis holds that every cell within the tumor population 
is  capable  of  tumor  initiation  and  propagation,  the 
cancer  stem  cell  model  proposes  that  only  a  small 
fraction of cells possesses the ability to initiate cancer 
growth and promote metastatic dissemination20.  
There are various methods of CSC identification 
in vitro; however, there is currently no consensus on a 
universally  acceptable  method15-18,20,23.  For  technical 
reasons, the most commonly utilized method of iden-
tification involves separating cells based on proteins 
thought  to  be  associated  with  the  cancer  stem  cell 
phenotype26.  Detection  of  sub-populations  of  cells 
such as CRCSC in regional nodes negative for tumor 
cells by conventional histopathology, or as circulating 
cells in the blood or bone marrow, is likely to increase 
accuracy of both cancer staging and prognosis. While 
some studies have linked CSC markers to prognosis, 
there remains no definitive association between puta-
tive CSC markers and disease behavior, disease pro-
gression, or survival. An association between putative 
CRCSC markers and survival could not only improve 
cancer  screening  and  early  detection,  but  also  help 
define optimal post-treatment follow up. Equally as 
important,  CRCSC  markers  could  potentially  tailor 
more  efficacious  treatment  modalities  to  those  pa-
tients  who  stand  to  benefit  most,  such  as  at-risk 
node-negative  (early  stage)  CRC  patients  who  are 
prone to recur.  
Molecular biomarkers provide potential benefits 
because they enable identification of specific cell types 
and cell populations that are associated with disease 
behavior and clinical outcomes 26. Methods of cancer 
stem cell identification are based on markers specific 
for  normal  progenitor  or  stem  cells  in  the  same 
organ27. The adult stem cells of the colon are of par-
ticular  interest  because  they  sustain  the  perpetual 
self-renewal  of  healthy  colonic  epithelium  and  are 
therefore  able  to  acquire  the  number  of  mutations 
required for carcinogenesis26. Although initial reports 
identified CD133 as a reliable CSC marker in colorec-
tal cancer, subsequent studies have shown that CD133 
expression is not restricted to rare cell subsets and it is 
detectable in a large majority of tumor cells, irrespec-
tive of their tumorigenicity23. Lugli et al also stated 
that neither  over-expression nor loss of CD133 was 
significantly  associated  with  tumor  progression  or 
survival23. Alternatively, CD29, C44, EpCAM, CD166, 
ALDH1A1 and ALDH1B1 were reported to identify 
another CSC pool23,28. Presence of these proteins has 
been associated with characteristics of stemness both 
in vitro and in vivo 20. Cells positive for these markers 
have been shown to generate tumors recapitulating 
the primary tumor with increased clonogenic ability 
and multi-lineage potential 20. This subset of cells has 
also been associated with tumor stage, differentiation, 
invasiveness,  metastasis  formation,  and  prognosis20. 
However, there is a paucity of longitudinal data in 
order  to  more  fully  understand  the  related  disease 
biology, as is presented in our study. 
Uncertainty remains as to whether CSC markers 
exclusively  delineate  the  stem  cell  population  and 
whether  they  can  predict  disease  behavior  26,  4.  In 
normal colon, CD29 has been observed in the lower 
parts of the crypts and therefore has been hypothe-
sized to be a mucosal progenitor cell marker29. The 
combination of CD24 and CD29 has been suggested to 
identify the tumor initiating fraction in mouse colon 
carcinomas29 and it is proposed that CD29 may pro-
mote  cancer  progression  by  inducing  invasion,  mi-
gration and metastasis through regulation of the tu-
mor microenvironment 29,30. Zou et al also stated that 
the  CD133+CD29+  cellular  fraction  up-regulated 
self-renewal,  proliferation  and  differentiation,  and 
therefore reported CD29 to be a new stem cell marker 
for colon cancer,30 although its full biological function 
has yet to be elucidated. Here we present the first re-
port  of  the  possible  association  between  CD29  ex-
pression and overall survival in CRC, which remains 
to some degree even after adjustment for stage in this 
limited size study.   Journal of Cancer 2012, 3 
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CD44, the first stem cell marker to be identified 
in breast cancer, has long been thought to be a marker 
of tumor invasiveness and metastasis, and more re-
cently  has  been  described  as  a  potential  CRCSC 
marker21,23.  CD44  is  a  transmembrane  glycoprotein 
that  can  act  as  a  receptor  for  extracellular  matrices 
such as hyaluronic acid; it is a downstream target of 
the  Wnt/B-catenin  pathway21.  High  expression  of 
CD44  in  malignant  colonic  epithelial  cells  has  been 
associated with tumor virulence; knockdown of CD44 
in primary colon cancer cell lines reduced clonogen-
icity in vitro and tumorigenicity in vivo29. Currently, it 
is not known whether CD44 is a specific marker for 
stem  cells,  as  a  large  population  of  CD44-exressing 
cells within a tumor has many splice variants21. Early 
reports of the CD44 gene and its splice variants de-
scribe decreased overall survival in patients with in-
creased  expression  levels  of  the  gene  or  its  related 
protein.  More  recent  results,  however,  are  incon-
sistent; some suggest either no role for CD44, others 
demonstrate  a  worse  clinical  outcome  with  loss  of 
protein expression 31,32,33,23. Further, some have identi-
fied increased expression of CD44 in colon along the 
progression from normal colonic epithelium to ade-
noma to carcinoma33,23. We did not find CD44 to be 
prognostic.  
Epithelial cell adhesion molecule (EpCAM) is a 
transmembrane  glycoprotein  mediating  epitheli-
um-specific intercellular adhesion. It is also a mole-
cule involved in cell signaling,  migration, prolifera-
tion  and  differentiation34.  As  EpCAM  is  expressed 
wholly in epithelium-derived cancers, it has been re-
ported  as  a  diagnostic  marker34.  Enhanced  EpCAM 
expression has been linked to advanced cancer stage 
and  worse  overall  survival34,  specifically  for  breast 
cancer and gallbladder cancer35,36. EpCAM expression 
has also been linked to higher primary tumor grade 
and inferior local and distant recurrence free survival 
in rectal cancer37. Lugli et al. also noted EpCAM to be 
a  prognostic  marker;  however,  they  found  a  de-
creased  expression  of  EpCAM  to  be  prognostic.  In 
addition, decreased EpCAM expression was found to 
be  significantly  associated  with  infiltrating  tumor 
margin, tumor invasion, and presence of lymph node 
metastasis23. Similarly, we found that decreased Ep-
CAM expression is associated with increasing lymph 
node stage (N0 vs. N1 vs. N2).  
CD166 expression can be used to further select 
CSC’s  within  the  EpCAM(+)CD44(+)  population  21. 
There  appears  to  be  heterogeneous  expression  of 
CD166 in CRC and the expression level is associated 
with poor clinical outcomes. It has been hypothesized 
that this effect is possibly mediated by CD166 regula-
tion of cell-to-cell interactions29. In immunodeficient 
mice, CD44+CD166+ colon cancer cells display high 
tumor initiating potential29. Patel et al. found a sig-
nificant increase in CD166 expression in adenomatous 
glands and an age-dependent increase in CD44 and 
CD166 expression. This was also associated with the 
number of colon polyps23,38. Weichert et al. described 
increased expression of CD166 in tumor tissue, and, in 
a  group  of  111  colorectal  cancer  cases,  observed  a 
between  CD166  expression  and  shortened  overall 
survival23,39.  These  findings  suggest  a  role  for  both 
CD44 and CD166 in the colon adenoma to carcinoma 
sequence.  It  is  possible  that  because  of  the  small 
number of patients analyzed in this study an associa-
tion between CD44, CD166 and outcomes could not 
be elucidated. 
CD24 has also been implicated in CRCSC’s. Choi 
et  al  examined  523  colorectal  adenocarcinomas  of 
various  stages  and  found  significant  correlation  be-
tween  CD24  expression  and  degree  of 
differentiation19,40. Other studies have shown that the 
degree of colorectal tumor CD24 expression is associ-
ated with lymph node metastasis and shortened pa-
tient survival 19,41,42. We chose not to use CD24 in this 
study. Although there may be a relationship between 
CD24 and oncologic outcome, the evidence for CD24 
as CRCSC marker is less convincing. 
ALDH1 has been reported as a cancer stem cell 
marker in pancreatic, breast, prostate, and lung can-
cer, multiple myeloma and leukemia. More recently 
ALDH1 was identified as a CRCSC marker21. ALDH1 
functions by catalyzing the irreversible oxidation of a 
range  of  aliphatic  and  aromatic  aldehydes  to  their 
corresponding carboxylic acids27. High ALDH1 activ-
ity is detected in stem and progenitor cells of various 
lineages. Enhanced ALDH1 expression was found in 
areas where epithelial progenitor cells localize within 
normal breast, colon and stomach27. Various groups 
have reported that high ALDH1 expression is associ-
ated  with  reduced  survival  times  in  breast,  lung, 
pancreas,  bladder  and  prostate  cancer  patients27. 
Deng et al. found that ovarian cancer patients with 
high  ALDH1  had  shorter  disease  free  and  overall 
survival  compared  to  those  with  low  ALDH1  (p  = 
0.0036 and p = 0.0023, respectively)27. Lugli et al. also 
noted that increased ALDH1 expression is associated 
with  higher  tumor  grade23.  We  similarly  found  an 
association  between  ALDH  expression  and  disease 
behavior.  
Although  this  study  is  the  first  to  analyze  the 
association  between  specific  biomarkers  within  a 
panel of six CRCSC markers and overall survival, the 
study has its limitations, particularly a small overall 
sample size. This specifically reduced our ability to 
describe tumor characteristics and behaviors accord- Journal of Cancer 2012, 3 
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ing  to  multi-marker  phenotype  of  the  investigated 
molecules,  and  required  us  to  conduct  the  analysis 
according to each marker individually. This parsimo-
nious analytical approach was done of necessity, as 
multi-marker phenotypes in tumor tissues are notably 
heterogeneous. The small number of matched normal 
controls  and  matched  metastatic  tissue  cores  is  an-
other limitation of this study. Finally, we were con-
strained by needing to use a retrospective study de-
sign. For this reason, we regard this study as hypoth-
esis generating in nature, and report our findings in 
the context of a pilot study. Therefore, the data should 
be interpreted with caution. Further prospective in-
vestigation  is  needed  to  validate  CRCSC  as  bi-
omarkers. 
The CSC hypothesis appears to have a promising 
role  in  CRC  tumor  biology,  despite  the  remaining 
unanswered questions related to this novel premise. 
By  focusing  on  the  identification  and  treatment  of 
tumor progenitor cells, we may ultimately be able to 
improve  screening,  early  detection,  treatment,  and 
prognostication19. Further identification of novel cell 
surface  or  cytoplasmic  markers  associated  with 
CRCSC,  and  validation  of  known  CRCSC  could  be 
useful  in  identifying  tumors  with  poor  prognosis. 
This  approach  could  further  enhance  our  ability  to 
assess  response  to  therapy  and  optimize  treatment 
selection and intensity of post-treatment surveillance 
and follow-up. In order to translate these findings into 
clinical practice, prospective comprehensive analysis 
of a panel  of CRCSC expression in large  groups of 
patients  is  imperative23.  Moreover,  there  remains  a 
paucity of data evaluating the prognostic significance 
of  the  co-expression  of  multiple  CRCSC  within  the 
same tumor, nodal and distant metastases within the 
same patients 14,23.  
Conclusion 
In this study, we have evaluated the relationship 
between the expression of six CRCSC markers, clini-
cally  relevant  features  and  outcomes.  Our  findings 
suggest  that  decreased  CD29  expression,  decreased 
EpCAM  expression  and  increased  ALDH1A1  and 
ALDH1B1  expression  may  represent  suitable 
risk-stratifying  worth  exploring  as  prognostic  bi-
omarkers  in  CRC.  These  findings  may  lend  them-
selves to a new strategy of individualized adjuvant 
therapy  selection  and  post-treatment  surveillance 
aimed at identifying patients with the highest likeli-
hood of disease recurrence or progression based on 
CRCSC marker expression within the primary tumor.  
The CSC hypothesis may herald a paradigm shift 
in oncologic diagnosis and treatment. This pilot study 
shows that putative CRC stem cell markers may have 
a role in predicting the behavior of CRC and estimat-
ing  clinical  outcomes.  Prospective  studies  properly 
powered based on this study should be undertaken to 
determine the significance of these early findings. 
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